ES2160098T3 - Fosforilasa de timidina que se utiliza en la modulacion de la proliferacion celular o de la quimiotaxis. - Google Patents

Fosforilasa de timidina que se utiliza en la modulacion de la proliferacion celular o de la quimiotaxis.

Info

Publication number
ES2160098T3
ES2160098T3 ES92922612T ES92922612T ES2160098T3 ES 2160098 T3 ES2160098 T3 ES 2160098T3 ES 92922612 T ES92922612 T ES 92922612T ES 92922612 T ES92922612 T ES 92922612T ES 2160098 T3 ES2160098 T3 ES 2160098T3
Authority
ES
Spain
Prior art keywords
phosphorilase
timidine
chemothotaxis
modulation
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922612T
Other languages
English (en)
Inventor
David James Ballance
Michael George Courtney
Christopher John Arthur Finnis
Darrell Sleep
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ES2160098T3 publication Critical patent/ES2160098T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

UNA FOSFORILASA TIMIDINA PARA USO EN MEDICINA. LA FOSFORILASA TIMIDINA DEBE SER TERMINADA A UN LUGAR SELECCIONADO, POR EJEMPLO POR CONJUGARLO A UN ANTICUERPO DIRIGIDO A UN ANTIGENO ESPECIFICO DE CELULA. LA FOSFORILASA TIMIDINA MODULA EL CRECIMIENTO DE LA CELULA Y/O PROMUEVE LA QUIMIOTAXIA. EL CRECIMIENTO DE LA CELULA PUEDE SER INCREMENTADO PARA LA CICATRIZACION DE HERIDAS O DISMINUIDO PARA LA TERAPIA DE TUMORES.
ES92922612T 1991-10-15 1992-10-15 Fosforilasa de timidina que se utiliza en la modulacion de la proliferacion celular o de la quimiotaxis. Expired - Lifetime ES2160098T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919121815A GB9121815D0 (en) 1991-10-15 1991-10-15 Medicine

Publications (1)

Publication Number Publication Date
ES2160098T3 true ES2160098T3 (es) 2001-11-01

Family

ID=10702923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922612T Expired - Lifetime ES2160098T3 (es) 1991-10-15 1992-10-15 Fosforilasa de timidina que se utiliza en la modulacion de la proliferacion celular o de la quimiotaxis.

Country Status (12)

Country Link
US (1) US6290953B1 (es)
EP (1) EP0618962B1 (es)
JP (1) JP3532193B2 (es)
AT (1) ATE202380T1 (es)
AU (1) AU664865B2 (es)
CA (1) CA2121358C (es)
DE (1) DE69231891T2 (es)
DK (1) DK0618962T3 (es)
ES (1) ES2160098T3 (es)
GB (1) GB9121815D0 (es)
GR (1) GR3036647T3 (es)
WO (1) WO1993008273A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501485B2 (en) * 2002-01-28 2009-03-10 Keraplast Technologies, Ltd. Bioactive keratin peptides
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178212A (en) * 1975-01-27 1979-12-11 Burroughs Wellcome Co. Stabilized thymidine phosphorylase formulation
US4347315A (en) 1980-04-25 1982-08-31 Burroughs Wellcome Co. Synthesis of ribosides using bacterial phosphorylase
ATE72122T1 (de) * 1987-04-24 1992-02-15 Wellcome Found Antivirale mischungen.
US5756686A (en) 1988-12-20 1998-05-26 Ludwig Institute For Cancer Research Peptides derived from endothelial cell growth factor
CA2005600A1 (en) * 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor
US5227302A (en) * 1988-12-20 1993-07-13 Ludwig Institute For Cancer Research DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Also Published As

Publication number Publication date
WO1993008273A1 (en) 1993-04-29
JPH07501938A (ja) 1995-03-02
DK0618962T3 (da) 2001-10-01
GB9121815D0 (en) 1991-11-27
ATE202380T1 (de) 2001-07-15
JP3532193B2 (ja) 2004-05-31
GR3036647T3 (en) 2001-12-31
CA2121358A1 (en) 1993-04-29
AU664865B2 (en) 1995-12-07
DE69231891D1 (de) 2001-07-26
US6290953B1 (en) 2001-09-18
EP0618962B1 (en) 2001-06-20
CA2121358C (en) 2003-12-30
EP0618962A1 (en) 1994-10-12
DE69231891T2 (de) 2002-03-28
AU2872892A (en) 1993-05-21

Similar Documents

Publication Publication Date Title
DE68922602D1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
DE69016827D1 (de) Leichte und flache phasengesteuerte Gruppenantenne mit elektromagnetisch gekoppelten integrierten Untergruppen.
DE68919176D1 (de) Faseroptische, gekrümmte Diffusionsplatte mit hohem Kontrast.
DK69890A (da) Monoklonale antistoffer, der er reaktive med cachetin
DE3787241D1 (de) Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung.
AU2953895A (en) Multi-stage cascade boosting vaccine
DE3889340D1 (de) Verbreitung von arzneimittelsystemen.
MX9301753A (es) Generacion in vitro de celulas dentriticas humanas y utilizacion de las mismas.
SG46455A1 (en) Intraoperative and endoscopic tumor detection and therapy
DE3587102D1 (de) Superstrahlungslichtquelle.
AU658198B2 (en) Tumour antigen specific antibody, its use and cell in line producing the antibody
IN168871B (es)
DE69522012T2 (de) Karzinombehandlung
KR970702733A (ko) 활성물질의 방출 조절용 콜라겐 제제(collagen preparation the controlled release of active substances)
GR900100372A (el) Προιον ζευξεως πολυπεπτιδιου-αντισωματος για την παρεμποδιση τησπροσφυσεως κυτταρων.
DE68922987D1 (de) Buchse mit verriegelung.
DE68905111D1 (de) Sonnenenergie-kontrollierender film.
DE68906198D1 (de) Lichterregbarer leuchtstoff und dessen verwendung in der radiographie.
ES2160098T3 (es) Fosforilasa de timidina que se utiliza en la modulacion de la proliferacion celular o de la quimiotaxis.
ES2118827T3 (es) Procedimiento y medio de cultivo celular para el cultivo de celulas animales adherentes.
ES2001013A6 (es) Un metodo para la preparacion de anticuerpos especificos de histamina
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
JPS5331236A (en) Infrared bulb for medical use
DK0514711T3 (da) Aspirintablet med pufret matrix

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 618962

Country of ref document: ES